Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;6(6):e21246.
doi: 10.1371/journal.pone.0021246. Epub 2011 Jun 23.

Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia

Theresa Guhr  1 , Judith Bloem, Ninotska I L Derksen, Manfred Wuhrer, Anky H L Koenderman, Rob C Aalberse, Theo Rispens
Affiliations

Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia

Theresa Guhr et al. PLoS One. 2011.

Abstract

Intravenous immunoglobulin G (IVIg) is widely used against a range of clinical symptoms. For its use in immune modulating therapies such as treatment of immune thrombocytopenic purpura high doses of IVIg are required. It has been suggested that only a fraction of IVIg causes this anti immune modulating effect. Recent studies indicated that this fraction is the Fc-sialylated IgG fraction. The aim of our study was to determine the efficacy of IVIg enriched for sialylated IgG (IVIg-SA⁺) in a murine model of passive immune thrombocytopenia (PIT). We enriched IVIg for sialylated IgG by Sambucus nigra agglutinin (SNA) lectin fractionation and determined the degree of sialylation. Analysis of IVIg-SA⁺ using a lectin-based ELISA revealed that we enriched predominantly for Fab-sialylated IgG, whereas we did not find an increase in Fc-sialylated IgG. Mass spectrometric analysis confirmed that Fc sialylation did not change after SNA lectin fractionation. The efficacy of sialylated IgG was measured by administering IVIg or IVIg-SA⁺ 24 hours prior to an injection of a rat anti-mouse platelet mAb. We found an 85% decrease in platelet count after injection of an anti-platelet mAb, which was reduced to a 70% decrease by injecting IVIg (p<0.01). In contrast, IVIg-SA⁺ had no effect on the platelet count. Serum levels of IVIg and IVIg-SA⁺ were similar, ruling out enhanced IgG clearance as a possible explanation. Our results indicate that SNA lectin fractionation is not a suitable method to enrich IVIg for Fc-sialylated IgG. The use of IVIg enriched for Fab-sialylated IgG abolishes the efficacy of IVIg in the murine PIT model.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Measurement of the degree of sialylation by SNA lectin inhibition ELISA.
% SNA lectin binding after pre-incubation A) with IVIg, IVIg-SA (+) or IVIg-SA (−) B) with Fab and Fc fragments derived from IVIg, IVIg-SA (+) or IVIg-SA (−) C) with Fab or protK digested Fab fragments derived from IVIg, IVIg-SA (+) or IVIg-SA (−) D) with Fc or protK digested Fc fragments derived from IVIg, IVIg-SA (+) or IVIg-SA (−). Data represents mean ± SEM, n = 3.
Figure 2
Figure 2. Mass spectrometric IgG1 Fc-glycosylation profiles of A) IVIg and B) IVIg-SA (+).
A) IVIg and B) IVIg-SA (+) were subjected to tryptic cleavage and analyzed by nanoLC-ESI-ion trap-mass spectrometry. Sum mass spectra of the elution range of the IgG1 Fc-glycopeptides are shown. Glycopeptides were registered as proton adducts ([M+4H]4+). All the displayed glycopeptides have 1 missed tryptic cleavage site and share the peptide moiety T289KPREEQFNSTFR301 carrying a glycan at N297. *, contaminant or irrelevant peak.
Figure 3
Figure 3. Schematic representation of the passive-immune thrombocytopenia mouse model.
Figure 4
Figure 4. Measured platelet count at t = 16 hours of the control groups.
Results are depicted as mean with error bars representing standard error of mean (SEM), (n = 10–12 mice per group). At t = −24 h, platelet counts were 913±52*109, 915±28*109, and 867±38*109 cells/L, respectively.
Figure 5
Figure 5. Measured platelet count at t = 16 hours after IVIg pre-treatment.
Pre-treatment with A) a high dose (1.5 g/kg) of IVIg, IVIg-SA (−), IVIg-SA (+), or saline. B) a low dose (0.3 g/kg) of IVIg, IVIg-SA (−) IVIg-SA (+), or saline. Results are depicted as mean with error bars representing standard error of mean (SEM), (n = 10–12 mice per group). * P<0.01.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kaveri SV, Dietrich G, Hurez V, Kazatchkine MD. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunol. 1991;86:192–198. - PMC - PubMed
    1. Gelfand EW. Treatment of autoimmune diseases with intravenous gammaglobulin. Semin Hematol. 1992;29:127–133. - PubMed
    1. Looney RJ, Huggins J. Use of intravenous immunoglobulin G (IVIG). Best Pract Res Clin Haematol. 2006;19:3–25. - PubMed
    1. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007;27:233–245. - PubMed
    1. Kumar A, Teuber SS, Gershwin ME. Intravenous immunoglobulin: striving for appropriate use. Int Arch Allergy Immunol. 2006;140:185–198. - PubMed

MeSH terms

-